

**Nickel-Catalyzed Reductive Conjugate Addition of Primary Alkyl Bromides to Enones to Form Silyl Enol Ethers**

Kierra M. M. Huihui, Ruja Shrestha, and Daniel J. Weix\*  
Department of Chemistry, University of Rochester, Rochester, NY, USA 14627

**Supporting Information**

## Table of Contents

I. General Information.....	3
II. Methods .....	4
III. General Procedures for Reductive Addition of Primary Unhindered Alkyl Halides to Enones .....	5
(A) Procedure for reactions set up in a glove box and run under nitrogen .....	5
(B) Large-Scale Procedure conducted on the benchtop in a round-bottom flask .....	5
IV. Procedures for Deprotection of Silyl Enol Ether Products from a Crude Reaction Mixture .....	6
V. Additional Experiments.....	7
<b>Table S1.</b> Effect of Ligand on Addition of 4-Bromoethylbutyrate ( <b>2a</b> ) to 2-Cyclohexen-1-one ( <b>1a</b> ). <sup>a</sup> ...	7
<b>Table S2.</b> Synergistic Effects of Solvent and M:L Ratio with <b>L6</b> <sup>a</sup> .....	8
<b>Table S3.</b> Analysis of <b>L7</b> by ESI+ MS after reaction is complete. ....	8
VI. Characterization Data.....	9
VI. Spectra .....	18

## I. General Information

### Metals:

NiCl<sub>2</sub>(1,2-dimethoxyethane) (NiCl<sub>2</sub>(dme)) was synthesized according to the literature procedure.<sup>1</sup> The stoichiometry of the NiCl<sub>2</sub>(dme) was found to be variable and the glyme is easily lost upon exposure to vacuum. The amount of glyme present in NiCl<sub>2</sub>(dme) was determined by elemental analysis and the molecular weight of NiCl<sub>2</sub>(dme) was calculated accordingly. Manganese powder -325 mesh (Aldrich) and zinc flake, -325 mesh (Alfa) were used as received. NiCl<sub>2</sub>(glyme), manganese powder, and zinc flake were stored in a Vacuum Atmospheres nitrogen filled glove box.

### Ligands:

6,6'-dibromo-2,2':6',2''-terpyridine (Aldrich) and 4,4',4''-tri-*tert*-butyl-2,2':6',2''-terpyridine (Aldrich) were used as received. 6,6'-Dimethyl-2,2':6',2''-terpyridine was synthesized according to the published procedure.<sup>2</sup> Other ligands tested were from commercial suppliers and used as received.

**Solvents:** Anhydrous *N,N*-dimethylacetamide (DMA), *N,N*-dimethylformamide (DMF), dimethoxyethane (DME), and tetrahydrofuran (THF) were obtained by passage of the ACS grade or better solvents through activated alumina and molecular sieves in a solvent purification system and were stored over 4 Å molecular sieves in a nitrogen filled glovebox.

**Enones:** 2-cyclohexen-1-one (Aldrich), 2-cyclopenten-1-one (Aldrich), 2-cyclohepten-1-one (Aldrich), 4-hexen-3-one (SAFC), 4,4-dimethyl-2-cyclohexen-1-one (Acros) were used as received.

**Alkyl Halides:** ethyl 4-bromobutyrate (Alfa), 1-bromooctane (Aldrich), 1-bromo-2-methylpropane (Aldrich), 4-bromobutyronitrile (TCI), 1-bromo-3-chloropropane (Aldrich), neopentyl bromide (Alfa), 1-(2-bromoethyl)-4-chlorobenzene (Combi), 2-(3-chlorophenyl)ethyl bromide (Combi), 1-phenyl-2-bromoethane (Acros), 3-bromopropionitrile (Alfa), 5-bromo-2-methyl-2-pentene (Aldrich), 2-(*tert*-butyldimethylsilyloxy)ethyl bromide (Oakwood), and 2-bromoethyl phenyl ether (Aldrich) were used as received. 3-bromopropylamine *tert*-butylcarbamate<sup>3</sup>, 5-bromo-2-pentanone<sup>4</sup>, benzyl *N*-(3-bromopropyl)carbamate<sup>5</sup>, 4-methoxyphenethyl bromide<sup>6</sup>, (5-bromopent-1-yn-1-yl)triisopropylsilane<sup>7</sup> were prepared according to literature procedures.

### Silylating Reagents:

All silyl reagents were purchased from Gelest and stored in a Vacuum Atmospheres nitrogen filled glove box. For the large scale reaction set up on the benchtop, the required amount of silyl reagent was removed from glove box in a sealed vial before use.

### Other Reagents:

Dodecane (Aldrich) was purchased commercially and used without further purification.

---

<sup>1</sup> Ward, L. G. L.; Pipal, J. R., *Inorg. Synth.* **2007**, *13*, 154.

<sup>2</sup> Sato, Y.; Nakayama Y.; Yasuda, H. *J. Organomet. Chem.* **2004**, *689*, 744.

<sup>3</sup> Huang, A. Y.-T.; Tsai, C.-H.; Chen, H.-Y.; Chen, H.-T.; Lu, C.-Y.; Ling, Y.-T.; Kao, C.-L. *Chem. Commun.* **2013**, *49*, 5784.

<sup>4</sup> Yu, F.; Miller, D. J.; Allemann, R. K. *Chem. Commun.* **2007**, *40*, 4155.

<sup>5</sup> Robarge, M. J.; Husbands, S. M.; Kieltyka, A.; Brodbeck, R.; Thurkauf, A.; Newman, A. H. *J. Med. Chem.* **2001**, *44*, 3175.

<sup>6</sup> Pitts, A. K.; O'Hara, F.; Snell, R. H.; Gaunt, M. J. *Angew. Chem., Int. Ed.* **2015**, *54*, 5451.

<sup>7</sup> Chen, C.; Layton, M. E.; Sheehan, S. M.; Shair, M. D. *J. Am. Chem. Soc.* **2000**, *122*, 7424.

## II. Methods

### **NMR Spectroscopy:**

$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were acquired on 400 and 500 MHz Bruker NMR instruments. NMR chemical shifts are reported in ppm and are referenced to the residual solvent peak for  $\text{CDCl}_3$  ( $\delta = 7.26$  ppm,  $^1\text{H}$  NMR;  $\delta = 77.16$  ppm,  $^{13}\text{C}$  NMR). Chemical shifts are reported in parts per million (ppm) and coupling constants ( $J$ ) are reported in Hertz, and integration is provided and assignments are indicated.

### **Gas Chromatography:**

GC analyses were performed on an Agilent 7890A GC equipped with dual DB-5 columns (20 m x 180  $\mu\text{m}$  x 0.18  $\mu\text{m}$ ), dual FID detectors, and hydrogen as the carrier gas. A sample volume of 1  $\mu\text{L}$  was injected at a temperature of 300  $^\circ\text{C}$  and a 100:1 split ratio. The initial inlet pressure was 20.3 psi but varied as the column flow was held constant at 1.8 mL/min for the duration of the run. The initial oven temperature of 50  $^\circ\text{C}$  was held for 0.46 min followed by a temperature ramp of 65  $^\circ\text{C}/\text{min}$  up to 300  $^\circ\text{C}$ . The temperature was held at 300  $^\circ\text{C}$  for 3 min. The total run time was  $\sim 7.3$  min and the FID temperature was 325  $^\circ\text{C}$ . Dodecane was used as an internal standard for GC analysis of catalytic reactions.

### **Gas Chromatography / Mass Spectrometry:**

GC/MS analyses were performed on a Shimadzu GCMS-QP2010 equipped with an RTX-XLB column (30 m x 0.25 mm x 0.28  $\mu\text{m}$ ) with a quadrupole mass analyzer using helium as a carrier gas. The analysis method used in all cases was 5  $\mu\text{L}$  injection of sample, an injection temperature of 225  $^\circ\text{C}$ , and a 25:1 split ratio. The initial inlet pressure was 7.8 psi, but varied as the column flow was held constant at 1.0 mL/min for the duration of the run. The interface temperature was held at 250  $^\circ\text{C}$ , and the ion source (EI+, 30 eV) was held at 250  $^\circ\text{C}$ . The initial oven temperature was held at 50  $^\circ\text{C}$  for 3 min with the detector off, followed by a temperature ramp, with the detector on, at 280  $^\circ\text{C}$  at 40  $^\circ\text{C}/\text{min}$ . The temperature was held at 280  $^\circ\text{C}$  for 3 min. The total run time was 11.75 min. Data are reported in the form of  $m/z$  (intensity relative to the base peak = 100 ion).

### **Liquid Chromatography Mass Spectrometry:**

LC/MS analyses were performed on a Shimadzu LC/MS 2010 equipped with an electrospray ionization (ESI) probe operating in positive ion mode (ESI+) with an ion trap mass analyzer. Direct injection analysis was employed in all cases with a sample solution in methanol.

### **High Resolution Mass Spectrometry:**

High resolution mass spectra (HRMS) under electron impact (EI+) or electrospray (ESI+) ionization methods were obtained from Mass Spectrometry Laboratory at University of Illinois at Champaign Urbana. The 70-VSE mass spectrometer (EI+ HRMS) was purchased in part with a grant from the Division of Research Resources, National Institutes of Health (RR 04648). The Q-TOF Ultima (ESI HRMS) mass spectrometer was purchased in part with a grant from the National Science Foundation, Division of Biological Infrastructure (DBI-0100085).

### **Thin Layer / Column Chromatography:**

Thin layer chromatography was performed on EMD Chemicals TLC Silica Gel 60 F254 plates. All plates used in isolation of silyl enol ethers were pre-treated with 0.1% trimethylamine. The remaining solvent was removed under reduced pressure. Visualization was accomplished with *p*-anisaldehyde (PNA) or potassium permanganate after inspection under UV light. Flash chromatography was performed using EMD silica gel 60, particle size 0.040-0.063 mm using standard flash techniques.

**Elemental Analysis:**

Elemental analysis data was obtained from the CENTC Elemental Analysis Facility at the University of Rochester, funded by NSF CHE-0650456.

### III. General Procedures for Reductive Addition of Primary Unhindered Alkyl Halides to Enones

**(A) Procedure for reactions set up in a glove box and run under nitrogen**

Reactions were set up in a Vacuum Atmospheres nitrogen filled glove box. To an oven-dried 1-dram vial containing a Teflon-coated stir-bar was added NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL, internal standard), enone (1.00 mmol, 1.00 equiv), alkyl bromide (1.10 mmol, 1.10 equiv), and silylating reagent (1.10 mmol, 1.10 equiv). The reaction vials were capped with a PTFE-faced silicone septum, removed from the glove box and heated in a reaction block set at 40 °C on the benchtop with stirring at 1200 rpm until the reaction was judged complete (<5% enone or alkyl bromide remaining) by GC analysis, typically 18–24 h.

**GC Analysis.**

After 18–24 h, a 10 μL aliquot of the reaction mixture was removed with a 50 μL gas-tight syringe. The aliquot was diluted with diethyl ether (1.5 mL), quenched with 10 μL of 1 M aqueous NaHSO<sub>4</sub>, and filtered through a short silica plug (1.5 cm) in a pipette packed with glass wool. The filtrate was analyzed by gas chromatography and percent yield was calculated versus dodecane as an internal standard.

**Isolation and Purification.**


Upon completion (<5% enone or alkyl bromide remaining) by GC analysis the reaction mixture was filtered through a short plug of silica gel (1.5 cm wide × 2 cm high) to remove metal salts and eluted with diethyl ether (100 mL). The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography using silica gel that was pre-treated with 0.1% triethylamine.<sup>8</sup> The purity of the desired product was determined by gas chromatography and <sup>1</sup>H NMR spectroscopy.

**(B) Large-Scale Procedure conducted on the benchtop in a round-bottom flask**

To a flame-dried 50 mL round-bottom flask containing a Teflon-coated stir-bar was added NiCl<sub>2</sub>(glyme) (49.4 mg, 0.240 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (188 mg, 0.48 mmol, 0.0800 equiv), Mn<sup>0</sup> (659 mg, 12 mmol, 2 equiv), THF (12 mL), 2-cyclohexene-1-one (618 μL, 6.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (945 μL, 6.6 mmol, 1.1 equiv), and triethylchlorosilane (1.1 mL, 6.6 mmol, 1.1 equiv). The reaction flask was sealed with a rubber septum, and the septum was fitted with a needle connected to an oil bubbler and a needle connected to a nitrogen manifold. The headspace of the reaction mixture was purged with nitrogen gas for ten minutes. The reaction mixture was warmed to 40 °C in an oil bath and stirred at that temperature under a positive flow of nitrogen. After the reaction was judged complete by GC analysis (~ 18 h), the reaction mixture was filtered through a plug of silica gel (1.5 cm wide × 3 cm high). The silica gel pad was washed with diethyl ether (300 mL) and combined filtrates were concentrated under reduced pressure. The resulting residue was purified by column chromatography using silica that was pre-treated with 0.1% triethylamine to yield 1.63 g of **4a** (83% yield). Characterization data matched those obtain on 1.0 mmol scale (vide infra).

<sup>8</sup> In several cases, we observed small amounts of isomerization of the silyl enol ether during column chromatography and storage. The other enol ether isomer is visible as a second vinyl hydrogen signal in the <sup>1</sup>H NMR spectrum and crude <sup>1</sup>H NMR spectra did not display this extra peak. We were unable to reproduce this phenomenon when we reran these reactions, but our working hypothesis is that this occurred with silica gel that had been insufficiently deactivated with triethylamine.

#### IV. Procedures for Deprotection of Silyl Enol Ether Products from a Crude Reaction Mixture<sup>9</sup> (Scheme 1, 4c)




General procedure **A** was followed with 2-cyclohexene-1-one (103  $\mu$ L, 1.00 mmol, 1.00 equiv), ethyl 4-bromobutanoate (157  $\mu$ L, 1.10 mmol, 1.10 equiv), and trimethylsilylchloride (140  $\mu$ L, 1.10 mmol, 1.10 equiv). Upon completion (judged as <5 Area % of starting materials remaining by GC analysis) the reaction mixture was filtered through a short plug of silica gel (1.5 cm wide  $\times$  2 cm high) and eluted with diethyl ether (100 mL). The filtrate was concentrated under reduced pressure. The resulting residue was dissolved in methanol (16 mL) and KF (116 mg, 2.00 mmol, 2.00 equiv) was added in small portions at room temperature. The resulting mixture was stirred for 30 minutes. Upon completion (judged as <1 Area% of silyl enol ether product remained by GC analysis) the solvent was removed under reduced pressure and the resulting residue was purified using silica gel chromatography.


<sup>9</sup> (a) Shrestha, R.; Dorn, S. C. M.; Weix, D. J. *J. Am. Chem. Soc.* **2013**, *135*, 751; (b) Oppolzer, W.; Snowden, R. L. *Helv. Chim. Acta* **1981**, *64*, 2592.

## V. Additional Experiments

**Table S1.** Effect of Ligand on Addition of 4-Bromoethylbutyrate (**2a**) to 2-Cyclohexen-1-one (**1a**).<sup>a</sup>



<sup>a</sup> General Procedure **A** was followed, reactions were run on a 0.5 mmol scale for 18 – 24 h in 1 mL of solvent, corrected GC yields of **4a** vs. dodecane as an internal standard. <sup>b</sup> All starting materials consumed, dimerized byproducts observed (**5**).

**Table S2.** Synergistic Effects of Solvent and M:L Ratio with **L6**<sup>a</sup>

entry	Solvent	mol % <b>L6</b>	yield <b>4a</b> <sup>b</sup> (%)	yield <b>5</b> (%)
1	DMF	4	0	71
2	DMF	8	<5	67
3	THF	4	11	61
4	THF	8	72	19

<sup>a</sup> General Procedure A was followed; reactions were run on a 0.5 mmol scale for 18 – 24 h in 1 mL of solvent. <sup>b</sup> Corrected GC yields of **4a** vs. dodecane as an internal standard.

**Table S3.** Analysis of **L7** by ESI+ MS after reaction is complete.

LC/MS *m/z* (% relative intensity, ion)


<b>L7:</b> R <sup>1</sup> = R <sup>2</sup> = Br	414.10 (5.07, M+Na <sup>+</sup> )
<b>L9:</b> R <sup>1</sup> = H, R <sup>2</sup> = (CH <sub>2</sub> ) <sub>3</sub> CO <sub>2</sub> Et	370.00 (9.67, M+Na <sup>+</sup> )
<b>L10:</b> R <sup>1</sup> = R <sup>2</sup> = (CH <sub>2</sub> ) <sub>3</sub> CO <sub>2</sub> Et	485.05 (4.64, M+Na <sup>+</sup> )

<sup>a</sup> General Procedure A was followed to form **4a**; reaction was run on a 0.5 mmol scale for 18 h in 1 mL of solvent (THF). A sample of the reaction mixture was diluted in methanol and infused into the mass spectrometer. The spectrum was searched for peaks with masses attributable to ligand derivatives.



## VI. Characterization Data

### Ethyl 4-(3-((triethylsilyloxy)cyclohex-2-en-1-yl)butanoate (Scheme 1, 4a)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157 μL, 1.10 mmol, 1.10 equiv), and chlorotriethylsilane (185 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 265 mg, 81% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.23 (3% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 4.78 (s, 1H), 4.12 (q, *J* = 7.1 Hz, 2H), 2.28 (t, *J* = 7.5 Hz, 2H), 2.12 (d, *J* = 0.7 Hz, 1H), 1.98 (s, 2H), 1.76-1.60 (m, 4H), 1.58-1.51 (m, 1H), 1.28 (dt, *J* = 19.4, 7.4 Hz, 5H), 1.09 (q, *J* = 10.9 Hz, 1H), 0.97 (t, *J* = 7.9 Hz, 9H), 0.65 (q, *J* = 7.9 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 173.8, 150.8, 108.8, 60.2, 36.6, 34.7, 34.5, 30.1, 28.8, 22.6, 21.9, 14.3, 6.8, 5.2.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV): 326.20 (3.14, M<sup>+</sup>), 211.15 (100.00, M<sup>+</sup>- C<sub>6</sub>H<sub>11</sub>O<sub>2</sub>), 115.10 (23.97, M<sup>+</sup>- C<sub>12</sub>H<sub>23</sub>OSi), 87.00 (14.34, M<sup>+</sup>- C<sub>14</sub>H<sub>27</sub>OSi)

**HRMS** (ESI+): [M+Na]<sup>+</sup> Calc. for C<sub>18</sub>H<sub>34</sub>O<sub>3</sub>Si: 349.2169; found: 349.2180

### Ethyl 4-(3-((tripropylsilyloxy)cyclohex-2-en-1-yl)butanoate (Scheme 1, 4b)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 361 mg, 98% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.26 (3% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 4.75 (s, 1H), 4.12 (q, *J* = 7.1 Hz, 2H), 2.28 (t, *J* = 7.5 Hz, 2H), 2.13-2.11 (m, 1H), 1.99-1.92 (m, 2H), 1.75-1.50 (m, 6H), 1.43-1.21 (m, 13H), 1.04-0.96 (m, 9H), 0.64 (dd, *J* = 9.6, 7.0 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 173.9, 150.9, 108.8, 60.3, 36.6, 34.8, 34.5, 30.2, 28.9, 22.7, 21.9, 18.5, 17.2, 16.6, 14.4.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 368.10 (5.48, M<sup>+</sup>), 253.05 (100.00, M<sup>+</sup>-C<sub>6</sub>H<sub>11</sub>O<sub>2</sub>), 115.05 (47.05, M<sup>+</sup>-C<sub>15</sub>H<sub>29</sub>OSi), 73.00 (22.25, C<sub>18</sub>H<sub>35</sub>OSi)

**HRMS** (ESI+): [M+Na]<sup>+</sup> Calc. for C<sub>21</sub>H<sub>40</sub>O<sub>3</sub>Si: 391.2639; found: 391.2656

### Ethyl 4-(3-oxocyclohexyl)butanoate (Scheme 1, 4c)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157 μL, 1.10 mmol, 1.10 equiv), and chlorotrimethylsilane (140 μL, 1.10 mmol, 1.10 equiv). General Deprotect

Procedure IV was followed to afford the crude ketone product. Analytical data match those in the literature.<sup>10</sup>

**Yield:** 147 mg, 69% yield

<sup>10</sup> Blake, A. J.; Shannon, J.; Stephens, J. C.; Woodward, S. *Chem.-Eur. J.* **2007**, *13*, 2462.

**TLC:**  $R_f = 0.33$  (25% EtOAc in hexanes, potassium permanganate stain)


**$^1\text{H NMR}$**  (500 MHz;  $\text{CDCl}_3$ ):  $\delta$  4.13 (q,  $J = 7.1$  Hz, 2H), 2.43-2.24 (m, 5H), 2.04-1.98 (m, 2H), 1.92-1.89 (m, 1H), 1.80-1.76 (m, 1H), 1.66-1.61 (m, 3H), 1.41-1.30 (m, 3H), 1.27-1.19 (m, 3H).

**$^{13}\text{C NMR}$**  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  211.7, 176.8, 60.4, 48.2, 41.6, 38.9, 36.1, 34.4, 31.3, 25.3, 22.3, 14.4.

**GC-MS**  $m/z$  (% relative intensity, ion): (EI+, 30 eV) 212.10 (<1,  $\text{M}^+$ ), 97.00 (100,  $\text{M}^+ - \text{C}_6\text{H}_{11}\text{O}_2$ )

**HRMS** (ESI+):  $[\text{M} + \text{Na}]^+$  Calc. for  $\text{C}_{12}\text{H}_{20}\text{O}_3$ : 235.1305; found: 235.1306

#### Ethyl 4-(3-((tripropylsilyloxy)cyclopent-2-en-1-yl)butanoate (Scheme 1, 4d)



The general procedure was followed with  $\text{NiCl}_2(\text{glyme})$  (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv),  $\text{Mn}^0$  (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0  $\mu\text{L}$  internal standard), 2-cyclopenten-1-one (83.8  $\mu\text{L}$ , 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157  $\mu\text{L}$ , 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240  $\mu\text{L}$ , 1.10 mmol, 1.10 equiv).

**Yield:** 316 mg, 89% yield, clear, colorless oil

**TLC:**  $R_f = 0.27$  (3%  $\text{Et}_2\text{O}$  in hexanes) [plate pre-treated with 0.1%  $\text{Et}_3\text{N}$ , *p*-anisaldehyde stain]


**$^1\text{H NMR}$**  (400 MHz;  $\text{CDCl}_3$ ): 4.59 (s, 1H), 4.12 (q,  $J = 7.1$  Hz, 2H), 2.60-2.56 (m, 1H), 2.30-2.22 (m, 3H), 2.02 (dq,  $J = 13.1, 6.8$  Hz, 1H), 1.65-1.55 (m, 2H), 1.41-1.34 (m, 8H), 1.26 (q,  $J = 8.7$  Hz, 4H), 0.96 (t,  $J = 7.2$  Hz, 9H), 0.66 (t,  $J = 8.3$  Hz, 6H).

**$^{13}\text{C NMR}$**  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  173.9, 155.3, 106.6, 60.3, 41.7, 36.9, 34.8, 33.3, 28.3, 23.2, 18.4, 16.82, 16.75, 14.4.

**GC-MS**  $m/z$  (% relative intensity, ion): (EI+, 30 eV) 354.10 (3.35,  $\text{M}^+$ ), 239.05 (100.00,  $\text{M}^+ - \text{C}_6\text{H}_{11}\text{O}_2$ ), 87.00 (4.68,  $\text{M}^+ - \text{C}_{16}\text{H}_{31}\text{OSi}$ )

**HRMS** (ESI+):  $[\text{M} + \text{Na}]^+$  Calc.  $\text{C}_{20}\text{H}_{38}\text{O}_3\text{Si}$ : 355.2668; found: 355.2682

#### Ethyl 4-(3-((triethylsilyloxy)cyclopent-2-en-1-yl)butanoate (Scheme 1, 4e)



The general procedure was followed with  $\text{NiCl}_2(\text{glyme})$  (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv),  $\text{Mn}^0$  (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0  $\mu\text{L}$  internal standard), 2-cyclopenten-1-one (83.8  $\mu\text{L}$ , 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157  $\mu\text{L}$ , 1.10 mmol, 1.10 equiv), and chlorotriethylsilane (185  $\mu\text{L}$ , 1.10 mmol, 1.10 equiv).

**Yield:** 200 mg, 64% yield, clear, colorless oil

**TLC:**  $R_f = 0.31$  (3%  $\text{Et}_2\text{O}$  in hexanes) [plate pre-treated with 0.1%  $\text{Et}_3\text{N}$ , *p*-anisaldehyde stain]


**$^1\text{H NMR}$**  (400 MHz;  $\text{CDCl}_3$ ):  $\delta$  4.61 (d,  $J = 1.6$  Hz, 1H), 4.12 (q,  $J = 7.1$  Hz, 2H), 2.58 (dd,  $J = 8.1, 3.8$  Hz, 1H), 2.30-2.23 (m, 4H), 2.05-2.00 (m, 1H), 1.65-1.56 (m, 2H), 1.45-1.19 (m, 6H), 0.97 (t,  $J = 7.9$  Hz, 9H), 0.67 (q,  $J = 7.9$  Hz, 6H).

**$^{13}\text{C NMR}$**  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  173.9, 155.3, 106.7, 60.3, 41.7, 36.9, 34.7, 33.3, 28.3, 23.2, 14.4, 6.7, 4.9.

**GC-MS**  $m/z$  (% relative intensity, ion): (EI, 30 eV) 312.05 (2.53,  $\text{M}^+$ ), 197.05 (100.00,  $\text{M}^+ - \text{C}_6\text{H}_{11}\text{O}_2$ ), 115.00 (42.39,  $\text{M}^+ - \text{C}_{11}\text{H}_{21}\text{OSi}$ ), 87.00 (20.41,  $\text{M}^+ - \text{C}_{13}\text{H}_{25}\text{OSi}$ )

**HRMS** (ESI+):  $[\text{M} + \text{Na}]^+$  Calc. for  $\text{C}_{17}\text{H}_{32}\text{O}_3\text{Si}$ : 335.2018; found: 335.2022

#### Ethyl 4-(3-((tripropylsilyloxy)cyclohept-2-en-1-yl)butanoate (Scheme 1, 4f)



The general procedure was followed with  $\text{NiCl}_2(\text{glyme})$  (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv),  $\text{Mn}^0$  (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0  $\mu\text{L}$  internal standard), 2-cyclohepten-1-one (112  $\mu\text{L}$ , 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157  $\mu\text{L}$ , 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240  $\mu\text{L}$ , 1.10 mmol, 1.10 equiv).

**Yield:** 256 mg, 67% yield, clear, colorless oil

**TLC:**  $R_f = 0.20$  (2%  $\text{Et}_2\text{O}$  in hexanes) [silica gel treated with 0.1%  $\text{Et}_3\text{N}$ , *p*-anisaldehyde]


**<sup>1</sup>H NMR** (500 MHz; CDCl<sub>3</sub>): δ 4.74 (d, *J* = 3.5 Hz, 1H), 4.12 (q, *J* = 7.1 Hz, 2H), 2.23-2.35 (m, 3H), 2.07 (dd, *J* = 14.9, 7.6 Hz, 2H), 1.87-1.85 (m, 1H), 1.61 (td, *J* = 15.3, 6.8 Hz, 4H), 1.52-1.24 (m, 14H), 0.96 (t, *J* = 7.1 Hz, 9H), 0.63 (t, *J* = 8.2 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 173.9 155.1, 113.4, 60.3, 37.1, 36.1, 35.4, 30.1, 26.7, 25.4, 22.9, 18.5, 17.1, 17.1, 16.9, 14.4.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 382.05 (9.74, M<sup>+</sup>), 267.05 (100.00, M<sup>+</sup>-C<sub>6</sub>H<sub>11</sub>O<sub>2</sub>), 225.00 (5.91, M<sup>+</sup>-C<sub>9</sub>H<sub>21</sub>Si) 157.05 (13.93, M<sup>+</sup>-C<sub>3</sub>H<sub>21</sub>O<sub>3</sub>), 115.00 (36.33, M<sup>+</sup>-C<sub>16</sub>H<sub>31</sub>OSi), 87.00 (8.48, M<sup>+</sup>-C<sub>18</sub>H<sub>35</sub>OSi)

**HRMS** (ESI+): [M+Na]<sup>+</sup> Calc. C<sub>22</sub>H<sub>42</sub>O<sub>3</sub>Si: 405.2801; found: 405.2804

#### Ethyl 4-(6,6-dimethyl-3-((tripropylsilyloxy)cyclohex-2-en-1-yl)butanoate (Scheme 1, 4g)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 4,4-dimethyl-2-cyclohexen-1-one (131.55 μL, 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 246, 62% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.21 (3% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 4.76 (s, 1H), 4.13 (q, *J* = 7.1 Hz, 2H), 2.30 (dt, *J* = 7.9, 6.3 Hz, 2H), 2.04-1.73 (m, 4H), 1.61-1.34 (m, 10H), 1.23 (dt, *J* = 17.9, 8.3 Hz, 4H), 0.95 (dd, *J* = 16.1, 8.8 Hz, 9H), 0.92 (s, 3H), 0.75 (s, 3H), 0.66-0.62 (m, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 173.8, 149.8, 106.6, 60.3, 44.2, 36.6, 34.8, 31.7, 30.7, 28.5, 27.6, 23.6, 21.7, 18.5, 17.2, 16.9, 14.4.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 396.10 (5.43, M<sup>+</sup>), 381.10 (3.47, M<sup>+</sup>-CH<sub>3</sub>) 353.10 (5.34, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 309.10 (5.46, M<sup>+</sup>-C<sub>4</sub>H<sub>7</sub>O<sub>2</sub>) 281.10 (100.00, M<sup>+</sup>-C<sub>6</sub>H<sub>11</sub>O<sub>2</sub>), 115.00 (39.60, M<sup>+</sup>-C<sub>17</sub>H<sub>33</sub>OSi), 87.00 (13.15, M<sup>+</sup>-C<sub>19</sub>H<sub>37</sub>OSi)

**HRMS** (EI+): [M+H]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>44</sub>O<sub>3</sub>Si: 397.3138; found: 397.3123

#### Ethyl-5-methyl-7-((trimethylsilyloxy)non-6-enoate (Scheme 1, 4h)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), *E*-4-hexen-3-one (115 μL, 1.00 mmol, 1.00 equiv), ethyl 4-bromobutyrate (157 μL, 1.10 mmol, 1.100 equiv), and trimethylchlorosilane (140 μL, 1.10 mmol, 1.10 equiv). The product was isolated as an inseparable mixture of *E* and *Z* isomers (1:4 by comparison of the <sup>1</sup>H NMR spectrum to the closely related butyl addition products<sup>11</sup>).

**Yield:** 240 mg, 84% yield, clear, colorless oil (*Z/E* ratio = 3.8:1)

**TLC:** R<sub>f</sub> = 0.21 (3% Et<sub>2</sub>O in hexanes) [silica gel treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde]

**<sup>1</sup>H NMR** (500 MHz; CDCl<sub>3</sub>): [(*Z*)-4h]: δ 4.21 (d, *J* = 3.0 Hz, 1 H) 4.11 (q, *J* = 7.1 Hz, 2H), 2.50-2.42 (m, 1H), 2.26 (t, *J* = 15.1 Hz, 2H), 2.00 (q, *J* = 21.8 Hz, 2H), 1.60 (dt, *J* = 56.5, 12.8 Hz, 2H), 1.33-1.14 (m, 5H), 1.01 (t, *J* = 7.4 Hz, 3H), 0.90 (d, *J* = 6.7 Hz, 3H), 0.18 (s, 9H); [(*E*)-4h]: 4.34 (d, *J* = 2.1 Hz, 1 H), 4.11 (q, *J* = 7.1 Hz, 2H), 2.48-2.44 (m, 1H), 2.26 (t, *J* = 15.0 Hz, 2H), 2.05 (q, *J* = 14.6 Hz, 2H), 1.60 (dt, *J* = 56.5, 12.8 Hz, 2H), 1.33-1.14 (m, 5H), 1.01 (t, *J* = 7.4 Hz, 3H), 0.93 (d, *J* = 6.67 Hz, 3H), 0.18 (s, 9H).


**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): [(*Z*)-4h]: δ 174.1 151.2, 113.2, 60.2, 37.4, 34.69, 31.9, 29.6, 23.2, 21.3, 14.4, 12.0, 0.84; [(*E*)-4h]: 174.1, 151.2, 113.8, 60.2, 37.8, 34.61, 31.9, 29.6, 24.9, 23.3, 22.5, 12.2, 0.55.

<sup>11</sup> Bergdahl, M.; Eriksson, M.; Nilsson, M.; Olsson, T. *J. Org. Chem.* **1993**, *58*, 7238-7244.

**GC-MS**  $m/z$  (% relative intensity, ion): (EI+, 30 eV) 286.20 (4.09, M<sup>+</sup>), 257.15 (3.43, M<sup>+</sup>-C<sub>2</sub>H<sub>5</sub>), 171.15 (100.00, M<sup>+</sup>-C<sub>6</sub>H<sub>11</sub>O<sub>2</sub>), 144.10 (12.36, M<sup>+</sup>-C<sub>7</sub>H<sub>15</sub>OSi), 129.05 (3.14, M<sup>+</sup>-C<sub>9</sub>H<sub>16</sub>O<sub>2</sub>), 73.05 (47.75, M<sup>+</sup>-C<sub>12</sub>H<sub>21</sub>O<sub>3</sub>)

**HRMS** (EI+): [M+H]<sup>+</sup> Calc. for C<sub>15</sub>H<sub>30</sub>O<sub>3</sub>Si: 287.2042; found: 287.2043

### ((3-octylcyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6a)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), bromooctane (190 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 349 mg, 95% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.69 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 4.78 (s, 1H), 2.10-2.06 (m, 1H), 2.01-1.92 (m, 2H), 1.75-1.66 (m, 2H), 1.53 (q, *J* = 7.7 Hz, 1H), 1.48-1.34 (m, 7H), 1.27 (s, 14H), 1.07 (dd, *J* = 21.2, 10.2 Hz, 1H), 0.96 (t, *J* = 7.2 Hz, 9H), 0.88 (t, *J* = 6.6 Hz, 3H), 0.64 (t, *J* = 8.3 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 150.2, 109.2, 37.0, 34.5, 31.8, 29.9, 29.8, 29.6, 29.3, 28.9, 26.9, 22.6, 21.8, 18.3, 16.9, 16.6, 14.0.

**GC-MS**  $m/z$  (% relative intensity, ion): (EI+, 30 eV) 366.15 (6.07, M<sup>+</sup>), 253.05 (100.00, M<sup>+</sup>-C<sub>8</sub>H<sub>17</sub>), 157.05 (8.91, M<sup>+</sup>-C<sub>14</sub>H<sub>25</sub>O)

**HRMS** (EI+): [M+H]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>46</sub>OSi: 367.3396; found: 367.3398

### ((3-neopentylcyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6b)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), neopentyl bromide (139 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 247 mg, 76% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.52 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (500 MHz; CDCl<sub>3</sub>): δ 4.82 (d, *J* = 1.3 Hz, 1H), 2.19 (ddd, *J* = 7.9, 5.2, 2.7 Hz, 1H), 1.98-1.93 (m, 2H), 1.75-1.66 (m, 2H), 1.59-1.51 (m, 1H), 1.44-1.36 (m, 6H), 1.26-1.09 (m, 3H), 0.97 (t, *J* = 7.3 Hz, 9H), 0.91 (s, 9H), 0.66-0.63 (m, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 149.7, 111.4, 51.5, 31.6, 31.2, 31.1, 30.1, 29.7, 21.9, 18.4, 17.1, 16.8.

**GC-MS**  $m/z$  (% relative intensity, ion): (EI+, 30 eV) 324.10 (7.07, M<sup>+</sup>), 253.05 (100.00, M<sup>+</sup>-C<sub>5</sub>H<sub>11</sub>), 157.00 (12.81, M<sup>+</sup>-C<sub>11</sub>H<sub>19</sub>O)

**HRMS** (EI+): [M+H]<sup>+</sup> Calc. for C<sub>20</sub>H<sub>40</sub>OSi: 325.2927; found: 325.2925

### ((3-phenethylcyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6c)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), 1-phenyl-2-bromoethane (150 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 334 mg, 93% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.3 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]

<sup>12</sup> Shrestha, R.; Weix, D. J. *Org. Lett.* **2011**, *13*, 2766.


**<sup>1</sup>H NMR** (500 MHz; CDCl<sub>3</sub>): δ 7.27 (t, *J* = 7.0 Hz, 2H), 7.8 (t, *J* = 8.2 Hz, 3H), 4.83 (s, 1H), 2.66-2.62 (m, 2H), 2.18-2.17 (m, 1H), 2.01-1.97 (m, 2H), 1.74-1.73 (m, 2H), 1.61-1.55 (m, 3H), 1.40 (dt, *J* = 15.9, 7.8 Hz, 6H), 1.26-1.14 (m, 1H), 0.97 (td, *J* = 7.2, 2.7 Hz, 9H), 0.66 (ddd, *J* = 9.7, 6.8, 2.7 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 150.9, 143.1, 128.5, 128.4, 125.7, 108.8, 39.2, 34.4, 33.6, 30.2, 29.1, 21.9, 18.5, 17.2, 16.9.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 358.10 (9.53, M<sup>+</sup>), 315.05 (14.04, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 253.05 (100.00, M<sup>+</sup>-C<sub>8</sub>H<sub>9</sub>), 157.05 (12.84, M<sup>+</sup>-C<sub>14</sub>H<sub>17</sub>O)

**HRMS** (EI+): [M]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>38</sub>OSi: 358.2692; found: 358.2690

### ((3-(4-methoxyphenethyl)cyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6d)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv) 4-methoxyphenethyl bromide (237 mg, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 353 mg, 91% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.264 (5% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR:** (400 MHz; CDCl<sub>3</sub>): δ 7.10 (d, *J* = 8.5 Hz, 2H), 6.83 (d, *J* = 8.6 Hz, 2H), 4.83 (d, *J* = 0.8 Hz, 1H), 3.79 (s, 3H), 2.58 (t, *J* = 8.0 Hz, 1H), 2.16-2.15 (m, 1H), 2.02-1.98 (m, 2H), 1.78-1.72 (m, 2H), 1.60-1.53 (m, 3H), 1.45-1.36 (m, 7H), 0.98 (t, *J* = 7.2 Hz, 9H), 0.68-0.64 (m, 6H).

**<sup>13</sup>C NMR:** (126 MHz, CDCl<sub>3</sub>): δ 157.8, 150.9, 135.1, 129.4, 113.9, 108.8, 55.4, 39.4, 34.3, 32.6, 30.2, 29.0, 21.9, 18.5, 17.2, 16.9.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 388.10 (5.18, M<sup>+</sup>), 345.10 (17.57, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 253.10 (100.00, M<sup>+</sup>-C<sub>9</sub>H<sub>11</sub>O), 215.00, (4.25, M<sup>+</sup>-C<sub>9</sub>H<sub>21</sub>OSi)

**HRMS** (EI+): [M+H]<sup>+</sup> Calc. for C<sub>24</sub>H<sub>40</sub>O<sub>2</sub>Si: 389.2876; found: 389.2873

### ((3-(4-chlorophenethyl)cyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6e)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), 1-(2-bromoethyl)-4-chlorobenzene (160 μL 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 362 mg, 92% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.47 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (500 MHz; CDCl<sub>3</sub>): (500 MHz; CDCl<sub>3</sub>): δ 7.24 (d, *J* = 8.2 Hz, 2H), 7.11 (d, *J* = 8.2 Hz, 2H), 4.80 (s, 1H), 2.60 (t, *J* = 8.0 Hz, 2H), 2.17-2.14 (m, 1H), 2.01-1.94 (m, 2H), 1.79-1.72 (m, 2H), 1.58-1.53 (m, 3H), 1.40 (dq, *J* = 15.7, 7.7 Hz, 6H), 1.16-1.14 (m, 2H), 0.97 (t, *J* = 7.2 Hz, 9H), 0.66 (dd, *J* = 9.9, 6.7 Hz, 6H)

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 151.1, 141.5, 131.5, 129.9, 128.5, 108.5, 39.0, 34.3, 32.9, 30.2, 29.0, 21.9, 18.5, 17.2, 16.9.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 392.00 (11.56, M<sup>+</sup>), 349.00 (12.24, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 253.10 (100.00, M<sup>+</sup>-C<sub>8</sub>H<sub>8</sub>Cl), 157.05 (12.42, M<sup>+</sup>-C<sub>14</sub>H<sub>16</sub>ClO)

**HRMS** (EI+): [M]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>37</sub>ClOSi: 392.2329; found: 392.2324

### ((3-(3-chlorophenethyl)cyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6f)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), 2-(3-chlorophenyl)ethyl bromide (242 mg, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 295 mg, 75% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.44 (100% hexanes) [silica gel treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde]


**<sup>1</sup>H NMR** (500 MHz; CDCl<sub>3</sub>): δ 7.18 (dq, *J* = 12.8, 6.8 Hz, 3H), 7.06 (d, *J* = 7.5 Hz, 1H), 4.81 (s, 1H), 2.61 (t, *J* = 8.0 Hz, 2H), 2.17-2.15 (m, 1H), 2.04-1.95 (m, 2H), 1.79-1.72 (m, 2H), 1.57 (tq, *J* = 14.5, 7.3 Hz, 3H), 1.41 (dq, *J* = 15.9, 7.8 Hz, 6H), 1.27-1.11 (m, 2H), 0.98 (t, *J* = 7.2 Hz, 9H), 0.66 (t, *J* = 8.3 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 151.2, 145.1, 134.2, 129.7, 128.7, 126.7, 125.9, 108.4, 38.8, 34.4, 33.3, 30.2, 28.9, 21.9, 18.5, 17.2, 16.9.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 392.00 (12.05, M<sup>+</sup>), 349.00 (10.62, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 253.10 (100.00, M<sup>+</sup>-C<sub>8</sub>H<sub>8</sub>Cl), 157.05 (12.42, M<sup>+</sup>-C<sub>14</sub>H<sub>16</sub>ClO)

**HRMS** (EI+): [M]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>37</sub>ClOSi: 392.2329; found: 392.2320

#### ((3-(4-methylpent-3-en-1-yl)cyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6g)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv) 5-bromo-2-methyl-2-pentene (147 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane

(240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 290 mg, 86% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.55 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 5.12 (s, 1H), 4.79 (s, 1H), 2.12 (s, 1H), 2.03-1.97 (m, 4H), 1.76-1.69 (m, 5H), 1.61 (s, 3H), 1.56-1.51 (m, 1H), 1.40 (dq, *J* = 15.9, 7.7 Hz, 6H), 1.30 (t, *J* = 7.5 Hz, 2H), 1.09 (d, *J* = 10.8 Hz, 1H), 0.97 (t, *J* = 7.2 Hz, 9H), 0.65 (dd, *J* = 10.0, 6.7 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 150.6, 131.3, 124.9, 109.1, 37.3, 34.4, 30.2, 29.1, 25.9, 25.7, 22.0, 18.5, 17.8, 17.2, 16.9.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 336.30 (37.05, M<sup>+</sup>), 293.25 (21.42, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 279.25 (M<sup>+</sup>-C<sub>4</sub>H<sub>9</sub>) 253.20 (62.08, M<sup>+</sup>-C<sub>6</sub>H<sub>11</sub>) 157.15 (M<sup>+</sup>-C<sub>12</sub>H<sub>19</sub>O).

**HRMS** (EI+): [M+H]<sup>+</sup> Calc. for C<sub>21</sub>H<sub>40</sub>OSi: 337.2927; found: 337.2919

#### ((3-(2-chloroethyl)cyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6h)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), 1-bromo-3-chloropropane (120 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 276 mg, 83% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.52 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 4.75 (s, 1H), 3.53 (t, *J* = 6.7 Hz, 2H), 2.15-2.12 (m, 1H), 2.03-1.92 (m, 2H), 1.83-1.68 (m, 4H), 1.59-1.49 (m, 1H), 1.39 (dd, *J* = 15.5, 7.4 Hz, 8H), 1.26 (s, 1H), 1.14-1.08 (m, 1H), 0.97 (t, *J* = 7.2 Hz, 9H), 0.64 (t, *J* = 8.3 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 151.1, 108.5, 45.5, 34.38, 34.25, 30.4, 30.1, 28.9, 21.9, 18.5, 17.2, 16.9.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 330.10 (7.94, M<sup>+</sup>), 253.05 (100.00, M<sup>+</sup>-C<sub>3</sub>H<sub>6</sub>Cl), 157.10 (14.56, M<sup>+</sup>-C<sub>9</sub>H<sub>14</sub>ClO)

**HRMS** (EI+): [M]<sup>+</sup> Calc. for C<sub>18</sub>H<sub>35</sub>ClOSi: 330.2146; found: 330.2149

### Triethyl(5-(3-((tripropylsilyl)oxy)cyclohex-2-en-1-yl)pent-1-yn-1-yl)silane (Scheme 2, 6i)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv) (5-bromopent-1-yn-1-yl)triisopropylsilane (332 mg, 1.10 mmol, 1.10 equiv), and chlorotriethylsilane (185 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 395 mg, 91% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.44 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 4.78 (s, 1H), 2.25 (t, *J* = 6.9 Hz, 2H), 2.14 (dd, *J* = 5.0, 2.2 Hz, 1H), 2.05-1.94 (m, 2H), 1.78-1.66 (m, 2H), 1.60-1.49 (m, 3H), 1.49-1.35 (m, 2H), 1.11-1.03 (m, 21H), 0.97 (t, *J* = 7.9 Hz, 9H), 0.65 (q, *J* = 7.9 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 150.7, 109.3, 109.1, 80.3, 36.2, 34.4, 30.1, 28.9, 26.5, 21.9, 20.2, 18.8, 11.5, 6.9, 5.2.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 434.40 (1.26, M<sup>+</sup>), 391.30 (7.73, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 277.20 (3.09, M<sup>+</sup>-C<sub>9</sub>H<sub>21</sub>Si), 237.20 (100.00, M<sup>+</sup>-C<sub>11</sub>H<sub>21</sub>OSi).

**HRMS** (EI+): [M]<sup>+</sup> Calc. for C<sub>26</sub>H<sub>50</sub>OSi<sub>2</sub> 434.3400; found: 434.3398

### 3-(3-((tripropylsilyl)oxy)cyclohex-2-en-1-yl)propanenitrile (Scheme 2, 6j)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), 3-bromopropanenitrile (91.3 μL 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv). Analytical data matches those in the literature.<sup>13</sup>

**Yield:** 280 mg, 91% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.18 (5% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


**<sup>1</sup>H NMR** (500 MHz; CDCl<sub>3</sub>): δ 4.68 (s, 1H), 2.33 (q, *J* = 8.3 Hz, 3H), 2.00-1.98 (m, 2H), 1.78-1.55 (m, 5H), 1.42-1.34 (m, 6H), 1.12 (t, *J* = 9.5 Hz, 1H), 0.96 (t, *J* = 7.3 Hz, 9H), 0.64 (dd, *J* = 9.9, 6.8 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz; CDCl<sub>3</sub>): δ 151.1, 119.5, 107.5, 35.8, 33.9, 29.8, 28.5, 22.8, 21.5, 18.1, 16.9, 16.6.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 307.10 (16.58, M<sup>+</sup>), 264.05 (100.00, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 222.05 (69.34, M<sup>+</sup>-C<sub>6</sub>H<sub>14</sub>), 157.10 (22.60, M<sup>+</sup>-C<sub>9</sub>H<sub>12</sub>NO)

**HRMS** (ESI+): [M+Na]<sup>+</sup> Calc. for C<sub>18</sub>H<sub>33</sub>NOSi: 330.2229; found: 330.2238

### ((3-(2-phenoxyethyl)cyclohex-1-en-1-yl)oxy)tripropylsilane (Scheme 2, 6k)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv) 2-bromoethyl phenyl ether (362 mg, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 273 mg, 73% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.29 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]

**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 7.30-7.26 (m, 2H), 6.93 (dd, *J* = 15.2, 7.6 Hz, 3H), 4.83 (d, *J* = 1.2 Hz, 1H), 4.02 (t, *J* = 6.6 Hz, 2H), 2.43-2.42 (m, 1H), 2.02-1.95 (m, 2H), 1.86-1.70 (m, 4H), 1.63-1.54 (m, 1H), 1.41 (quintet, *J* = 8.9 Hz, 6H), 1.23-1.18 (m, 1H), 0.99-0.95 (m, 9H), 0.68-0.64 (m, 6H).


<sup>13</sup> Streuff, J. *Chem.-Eur. J.* **2011**, *17*, 5507.

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 159.2, 151.2, 129.5, 120.6, 114.6, 108.3, 66.1, 36.4, 31.8, 30.1, 28.9, 21.8, 18.5, 17.2, 16.9.

GC-MS *m/z* (% relative intensity, ion): (EI+, 30 eV) 374.10 (2.98, M<sup>+</sup>), 331.10 (39.87, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 253.10 (100.00, M<sup>+</sup>-C<sub>8</sub>H<sub>9</sub>O) 157.10 (19.20, M<sup>+</sup>-C<sub>14</sub>H<sub>17</sub>O<sub>2</sub>)

HRMS (EI+): [M+H]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>38</sub>O<sub>2</sub>Si: 375.2719; found: 375.2729

### Tert-butyldimethyl(2-(3-((tripropylsilyloxy)cyclohex-2-en-1-yl)ethoxy)silane (Scheme 2, 6l)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv) 2-(tert-butyldimethylsilyloxy)ethyl bromide (236 μL, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 281 mg, 68% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.24 (100% hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


<sup>1</sup>H NMR (400 MHz; CDCl<sub>3</sub>): δ 4.77 (s, 1H), 3.66 (td, *J* = 6.6, 2.5 Hz, 2H), 2.27-2.26 (m *J* = 1.7 Hz, 1H), 1.97-1.96(m, *J* = 2.1 Hz, 2H), 1.75-1.65 (m, 2H), 1.58-1.46 (m, 3H), 1.42-1.36 (m, 7H), 0.96 (td, *J* = 7.2, 2.5 Hz, 10H), 0.89 (d, *J* = 2.5 Hz, 8H), 0.64 (dt, *J* = 8.2, 4.1 Hz, 6H), 0.05 (s, 6H).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 150.8, 108.8, 61.4, 40.1, 31.3, 30.2, 29.1, 26.1, 21.8, 18.5, 17.2, 16.9, -5.1

GC-MS *m/z* (% relative intensity, ion): (EI+, 30 eV)

HRMS (EI+): [M+H]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>48</sub>O<sub>2</sub>Si<sub>2</sub>: 413.3271; found: 413.3271

### Tert-butyl (3-(3-((tripropylsilyloxy)cyclohex-2-en-1-yl)propyl)carbamate (Scheme 2, 6m)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), 3-bromopropylamine tert-butylcarbamate (262 mg, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 375 mg, 91% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.225 (5% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]


<sup>1</sup>H NMR (400 MHz; CDCl<sub>3</sub>): δ 4.74 (s, 1H), 4.49 (td, *J* = 2.0, 0.8 Hz, 1H), 3.10-3.09 (m, 2H), 2.12-1.67 (m, 5H), 1.51-1.25 (m, 21H), 0.98-0.94 (m, 9H), 0.64 (td, *J* = 7.7, 3.5 Hz, 6H).

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 156.1, 150.9, 108.8, 79.1, 41.0, 34.5, 34.3, 30.2, 28.9, 28.6, 27.7, 21.9, 18.5, 17.2, 16.8

GC-MS *m/z* (% relative intensity, ion): (EI+, 30 eV) 411.00 (<1.00, M<sup>+</sup>), 354.10 (62.73, M<sup>+</sup>-C<sub>4</sub>H<sub>9</sub>), 338.10 (3.07, M<sup>+</sup>-C<sub>4</sub>H<sub>9</sub>O), 295.10 (3.25, M<sup>+</sup>-C<sub>5</sub>H<sub>10</sub>NO<sub>2</sub>), 253.10 (100.00, M<sup>+</sup>-C<sub>8</sub>H<sub>16</sub>NO<sub>2</sub>), 157.10 (25.37, M<sup>+</sup>-C<sub>14</sub>H<sub>24</sub>NO<sub>3</sub>), 116.05 (81.30, M<sup>+</sup>-C<sub>18</sub>H<sub>36</sub>OSi)

HRMS (ESI+): [M+Na]<sup>+</sup> Calc. for C<sub>23</sub>H<sub>45</sub>NO<sub>3</sub>Si: 434.3066; found: 434.3062

### Benzyl (3-(3-((tripropylsilyloxy)cyclohex-2-en-1-yl)propyl)carbamate (Scheme 2, 6n)



The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv) benzyl N-(3-bromopropyl)carbamate (299 mg, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 388 mg, 87% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.19 (5% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]



**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 7.36-7.32 (m, 5H), 5.09 (s, 2H), 4.73 (s, 2H), 3.19 (d, *J* = 5.7 Hz, 2H), 2.11 (dd, *J* = 2.9, 1.0 Hz, 1H), 1.96 (s, 2H), 1.75-1.67 (m, 2H), 1.52-1.50 (m, 3H), 1.42-1.36 (m, 6H), 1.27 (t, *J* = 7.3 Hz, 2H), 1.08 (t, *J* = 10.5 Hz, 1H), 0.98-0.94 (m, 9H), 0.64 (dd, *J* = 10.3, 6.1 Hz, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 156.4, 150.9, 136.8, 128.6, 128.2, 128.2, 108.7, 66.7, 41.5, 34.4, 34.2, 30.1, 28.9, 27.6, 21.8, 18.4, 17.1, 16.8.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 445.10 (<1.00, M<sup>+</sup>), 338.10 (7.21, M<sup>+</sup>-C<sub>7</sub>H<sub>7</sub>O), 253.05 (100.0, M<sup>+</sup>-C<sub>11</sub>H<sub>14</sub>NO<sub>2</sub>), 157.10 (17.42, M<sup>+</sup>-C<sub>17</sub>H<sub>22</sub>NO<sub>2</sub>) 115.00 (57.70, M<sup>+</sup>-C<sub>21</sub>H<sub>34</sub>OSi)

**HRMS** (ESI+): [M+Na]<sup>+</sup> Calc. for C<sub>26</sub>H<sub>43</sub>NO<sub>3</sub>Si: 446.3090, 446.3085

### 5-(3-((tripropylsilyloxy)cyclohex-2-en-1-yl)pentan-2-one (Scheme 2, 6o)

The general procedure was followed with NiCl<sub>2</sub>(glyme) (8.24 mg, 0.0400 mmol, 0.0400 equiv), 6,6'-dibromo-2,2':6',2''-terpyridine (31.3 mg, 0.0800 mmol, 0.0800 equiv), Mn<sup>0</sup> (110 mg, 2.00 mmol, 2.00 equiv), THF (2 mL), dodecane (10.0 μL internal standard), 2-cyclohexen-1-one (103 μL, 1.00 mmol, 1.00 equiv), 5-bromo-2-pentanone (182 mg, 1.10 mmol, 1.10 equiv), and tri-*n*-propylchlorosilane (240 μL, 1.10 mmol, 1.10 equiv).

**Yield:** 295 mg, 87% yield, clear, colorless oil

**TLC:** R<sub>f</sub> = 0.19 (5% Et<sub>2</sub>O in hexanes) [plate pre-treated with 0.1% Et<sub>3</sub>N, *p*-anisaldehyde stain]

**<sup>1</sup>H NMR** (400 MHz; CDCl<sub>3</sub>): δ 4.74 (s, 1H), 2.41 (t, *J* = 7.4 Hz, 2H), 2.13 (s, 4H), 1.98-1.90 (m, 2H), 1.76-1.65 (m, 2H), 1.63-1.49 (m, 3H), 1.42-1.33 (m, 6H), 1.29-1.18 (m, 2H), 1.07 (dd, *J* = 22.1, 10.1 Hz, 1H), 0.95 (t, *J* = 7.3 Hz, 9H), 0.65-0.61 (m, 6H).

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ 209.1, 150.8, 108.7, 44.1, 36.7, 34.6, 30.1, 29.9, 28.9, 21.9, 21.5, 18.4, 17.1, 16.8.

**GC-MS** *m/z* (% relative intensity, ion): (EI+, 30 eV) 338.10 (8.17, M<sup>+</sup>), 295.10 (4.50, M<sup>+</sup>-C<sub>3</sub>H<sub>7</sub>), 253.10 (100.00, M<sup>+</sup>-C<sub>5</sub>H<sub>9</sub>O), 157.10 (14.75, M<sup>+</sup>-C<sub>11</sub>H<sub>17</sub>O<sub>2</sub>)

**HRMS** (ESI+): [M+Na]<sup>+</sup> Calc. for C<sub>20</sub>H<sub>38</sub>O<sub>2</sub>Si: 361.2539; found: 361.2544

## VI. Spectra

